143 related articles for article (PubMed ID: 26395561)
1. Light pigmentation phenotype is correlated with increased substantia nigra echogenicity.
Rumpf JJ; Schirmer M; Fricke C; Weise D; Wagner JA; Simon J; Classen J
Mov Disord; 2015 Nov; 30(13):1848-52. PubMed ID: 26395561
[TBL] [Abstract][Full Text] [Related]
2. Structural abnormality of substantia nigra induced by methamphetamine abuse.
Rumpf JJ; Albers J; Fricke C; Mueller W; Classen J
Mov Disord; 2017 Dec; 32(12):1784-1788. PubMed ID: 29082542
[TBL] [Abstract][Full Text] [Related]
3. Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder.
Iranzo A; Stockner H; Serradell M; Seppi K; Valldeoriola F; Frauscher B; Molinuevo JL; Vilaseca I; Mitterling T; Gaig C; Vilas D; Santamaria J; Högl B; Tolosa E; Poewe W
Mov Disord; 2014 Dec; 29(14):1774-80. PubMed ID: 25384461
[TBL] [Abstract][Full Text] [Related]
4. Measurement of the adult human midbrain with transcranial ultrasound.
Aoun K; Double KL; Pearson-Dennett V; Yilmaz R; Berg D; Todd G
PLoS One; 2021; 16(3):e0247920. PubMed ID: 33647059
[TBL] [Abstract][Full Text] [Related]
5. Severity of restless legs syndrome is inversely correlated with echogenicity of the substantia nigra in different neurodegenerative movement disorders. a preliminary observation.
Pedroso JL; Bor-Seng-Shu E; Felicio AC; Braga-Neto P; Dutra LA; de Aquino CC; Ferraz HB; do Prado GF; Teixeira MJ; Barsottini OG
J Neurol Sci; 2012 Aug; 319(1-2):59-62. PubMed ID: 22632781
[TBL] [Abstract][Full Text] [Related]
6. No correlation of substantia nigra echogenicity and nigrostriatal degradation in Parkinson's disease.
Lobsien E; Schreiner S; Plotkin M; Kupsch A; Schreiber SJ; Doepp F
Mov Disord; 2012 Mar; 27(3):450-3. PubMed ID: 22237792
[TBL] [Abstract][Full Text] [Related]
7. Sonography for diagnosis of Parkinson disease-from theory to practice: a study on 300 participants.
Alonso-Cánovas A; López-Sendón JL; Buisán J; deFelipe-Mimbrera A; Guillán M; García-Barragán N; Corral I; Matute-Lozano MC; Masjuan J; Martínez-Castrillo JC; Walter U
J Ultrasound Med; 2014 Dec; 33(12):2069-74. PubMed ID: 25425362
[TBL] [Abstract][Full Text] [Related]
8. Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor.
Sprenger FS; Wurster I; Seppi K; Stockner H; Scherfler C; Sojer M; Schmidauer C; Berg D; Poewe W
Mov Disord; 2016 Apr; 31(4):579-83. PubMed ID: 26893155
[TBL] [Abstract][Full Text] [Related]
9. Substantia nigra echogenicity and imaging of striatal dopamine transporters in Parkinson's disease: a cross-sectional study.
Bor-Seng-Shu E; Pedroso JL; Felicio AC; de Andrade DC; Teixeira MJ; Braga-Neto P; Batista IR; Barsottini OG; Borges V; Ferraz HB; Shih MC; Bressan RA; de Andrade LA; Walter U
Parkinsonism Relat Disord; 2014 May; 20(5):477-81. PubMed ID: 24629800
[TBL] [Abstract][Full Text] [Related]
10. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography.
Becker G; Seufert J; Bogdahn U; Reichmann H; Reiners K
Neurology; 1995 Jan; 45(1):182-4. PubMed ID: 7824114
[TBL] [Abstract][Full Text] [Related]
11. Substantia nigra echogenicity correlated with clinical features of Parkinson's disease.
Zhou HY; Sun Q; Tan YY; Hu YY; Zhan WW; Li DH; Wang Y; Xiao Q; Liu J; Chen SD
Parkinsonism Relat Disord; 2016 Mar; 24():28-33. PubMed ID: 26842545
[TBL] [Abstract][Full Text] [Related]
12. Sonographic abnormality of the substantia nigra in melanoma patients.
Rumpf JJ; Weise D; Fricke C; Wetzig T; Simon JC; Classen J
Mov Disord; 2013 Feb; 28(2):219-23. PubMed ID: 23114984
[TBL] [Abstract][Full Text] [Related]
13. Effect of Age on Substantia Nigra Hyper-echogenicity in Parkinson's Disease Patients and Healthy Controls.
Toomsoo T; Liepelt-Scarfone I; Berg D; Kerner R; Pool AH; Kadastik-Eerme L; Rubanovits I; Asser T; Taba P
Ultrasound Med Biol; 2019 Jan; 45(1):122-128. PubMed ID: 30482710
[TBL] [Abstract][Full Text] [Related]
14. Hyperechogenicity of the substantia nigra in Parkinson's disease.
Ressner P; Skoloudík D; Hlustík P; Kanovský P
J Neuroimaging; 2007 Apr; 17(2):164-7. PubMed ID: 17441838
[TBL] [Abstract][Full Text] [Related]
15. [Usefulness of transcranial sonography in Parkinson's disease. A comparative study using 123I-FP-CIT SPECT].
Hernández Vara J; Rubiera del Fueyo M; Lorenzo Bosquet C; Castell Conesa J; Molina Cateriano CA; Rodríguez FM
Med Clin (Barc); 2008 Sep; 131(8):285-9. PubMed ID: 18803921
[TBL] [Abstract][Full Text] [Related]
16. Adults with a history of illicit amphetamine use exhibit abnormal substantia nigra morphology and parkinsonism.
Todd G; Pearson-Dennett V; Wilcox RA; Chau MT; Thoirs K; Thewlis D; Vogel AP; White JM
Parkinsonism Relat Disord; 2016 Apr; 25():27-32. PubMed ID: 26923520
[TBL] [Abstract][Full Text] [Related]
17. Life-long increase of substantia nigra hyperechogenicity in transcranial sonography.
Hagenah J; König IR; Sperner J; Wessel L; Seidel G; Condefer K; Saunders-Pullman R; Klein C; Brüggemann N
Neuroimage; 2010 May; 51(1):28-32. PubMed ID: 20152909
[TBL] [Abstract][Full Text] [Related]
18. Illicit stimulant use is associated with abnormal substantia nigra morphology in humans.
Todd G; Noyes C; Flavel SC; Della Vedova CB; Spyropoulos P; Chatterton B; Berg D; White JM
PLoS One; 2013; 8(2):e56438. PubMed ID: 23418568
[TBL] [Abstract][Full Text] [Related]
19. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J;
Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology of transcranial sonography signal changes in the human substantia nigra.
Double KL; Todd G; Duma SR
Int Rev Neurobiol; 2010; 90():107-20. PubMed ID: 20692497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
